Pf brings you its weekly drug approvals and appraisals with a raft of announcements from the Scottish Medicines Consortium, plus NICE and China National Medical Products Administration.
NICE has published draft guidance which does not recommend pembrolizumab (MSD’s Keytruda) with axitinib (Inlyta, Pfizer) for untreated advanced renal cell carcinoma (RCC) in adults.
Takeda has announced that the Scottish Medicines Consortium has accepted Revestive (teduglutide) for use in adult patients with short bowel syndrome (SBS), after previously issuing advice restricting its use to paediatric patients only (aged 1-17 years).
Pierre Fabre announced that the Scottish Medicines Consortium has accepted the targeted oral combination BRAFTOVI®▼ (encorafenib) plus MEKTOVI®▼ (binimetinib) for use on the NHS in Scotland to treat adult patients with unresectable or metastatic melanoma with a mutation in the BRAF V600 gene.
The SMC has granted conditional approval of Sanofi’s LIBTAYO® (cemiplimab) for use within NHS Scotland as monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
The SMC also published a negative recommendation for the use of AstraZeneca’s Lokelma (sodium zirconium cyclosilicate [SZC]) within NHS Scotland for the treatment of hyperkalaemia in adult patients. AstraZeneca expressed its disappointment at the decision, is addressing questions from the SMC and will be resubmitting SZC for reconsideration later this year.
Roche has announced that China National Medical Products Administration has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer.
Previous approvals and appraisals